Novo Nordisk A/S (NVO)

Hims & Hers Health jumps on earnings. CFO talks GLP-1 influences.

Hims & Hers Health (HIMS) shares jumped in extended trading after the company reported better than expected third quarter revenue and raised its outlook. The telehealth company swung to a profit, helped by a tax benefit and strong demand for GLP-1 weight-loss drugs. In an interview on Market Domination Overtime, Hims & Hers Health CFO Yemi Okupe speaks with anchors Julie Hyman and Josh Lipton about the quarter. "We saw revenue up 77% year-over-year to north of 4$00 million. Simultaneously, we're also seeing very strong EBITDA margins at north of 13%," Okupe says. "Additionally, at the end of the quarter, we also saw 2 million consumers on the platform, of which 1 million were benefiting from a personalized solution. And so really, the strong results that we're seeing in the third quarter are a reflection of us executing across the strategy that we've held for the past couple of years." Okupe also addresses a possible headwind for the company, that Eli Lilly (LLY)'s and Novo Nordisk (NVO)'s weight-loss drugs are coming off the FDA's (Food and Drug Administration) shortage lists. But Okupe says it's not a concern right now, but acknowledges the shortages will come to an end."In our view, we do still see that the medications are on on shortage. And what we do see on our platform. And this is the benefit of being a consumer oriented platform, is that we hear feedback directly from consumers and what consumers are telling us, you know resoundingly, is that they are struggling to get access to name-brand GLP-1 medications over the last two months," according to Okupe. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime here. This post was written by Rachel Sherman.

Viking Therapeutics stock falling amid results for new GLP-1 pill

Viking Therapeutics (VKTX) shares are taking a dive in Monday's session despite on rising manufacturing concerns and competition between pharmaceutical rivals in the GLP-1 weight-loss drug space. Viking reported positive results for its new obesity pill, its breakthrough overshadowed not too soon after by other names in the space. Julie Hyman and Josh Lipton report on the latest for Viking Therapeutics' phase 1 trial results and the latest out of the ObesityWeek conference in San Antonio, Texas. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. This post was written by Luke Carberry Mogan.

• 
  Viking Therapeutics' Hot Stock Slips After Latest Obesity Drug Trial Results

  Investopedia
• 
  Why Viking Therapeutics Stock Plummeted After Soaring Today

  Motley Fool